Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA) have earned an average rating of “Moderate Buy” from the nine brokerages that are presently covering the stock, Marketbeat reports. Two research analysts have rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $23.00.

A number of brokerages have commented on ZVRA. BTIG Research initiated coverage on Zevra Therapeutics in a research report on Monday, March 16th. They issued a “buy” rating and a $23.00 price objective on the stock. HC Wainwright set a $26.00 target price on Zevra Therapeutics in a research report on Tuesday, December 30th. Weiss Ratings raised Zevra Therapeutics from a “sell (d+)” rating to a “hold (c+)” rating in a research note on Tuesday, March 10th. Guggenheim set a $23.00 price target on Zevra Therapeutics and gave the company a “buy” rating in a report on Tuesday, March 10th. Finally, Wall Street Zen lowered Zevra Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, March 14th.

Insider Buying and Selling at Zevra Therapeutics

In other news, SVP Timothy J. Sangiovanni sold 3,000 shares of Zevra Therapeutics stock in a transaction that occurred on Tuesday, February 3rd. The shares were sold at an average price of $9.18, for a total transaction of $27,540.00. Following the completion of the sale, the senior vice president owned 29,590 shares in the company, valued at $271,636.20. The trade was a 9.21% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Joshua Schafer sold 10,500 shares of the business’s stock in a transaction that occurred on Tuesday, February 3rd. The stock was sold at an average price of $9.19, for a total transaction of $96,495.00. Following the sale, the insider directly owned 62,278 shares of the company’s stock, valued at approximately $572,334.82. This trade represents a 14.43% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 114,158 shares of company stock worth $1,062,878 over the last quarter. Company insiders own 2.40% of the company’s stock.

Institutional Trading of Zevra Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the business. CWM LLC lifted its stake in shares of Zevra Therapeutics by 399.5% in the 3rd quarter. CWM LLC now owns 2,872 shares of the company’s stock valued at $27,000 after purchasing an additional 2,297 shares during the period. Ameritas Investment Partners Inc. grew its stake in shares of Zevra Therapeutics by 30.0% during the second quarter. Ameritas Investment Partners Inc. now owns 5,541 shares of the company’s stock worth $49,000 after purchasing an additional 1,280 shares during the period. Gunpowder Capital Management LLC dba Oliver Wealth Management acquired a new stake in shares of Zevra Therapeutics during the fourth quarter worth $53,000. Russell Investments Group Ltd. increased its holdings in Zevra Therapeutics by 235.7% in the third quarter. Russell Investments Group Ltd. now owns 6,374 shares of the company’s stock valued at $61,000 after purchasing an additional 4,475 shares during the last quarter. Finally, Tower Research Capital LLC TRC lifted its stake in Zevra Therapeutics by 617.5% in the second quarter. Tower Research Capital LLC TRC now owns 9,937 shares of the company’s stock valued at $88,000 after buying an additional 8,552 shares during the period. Institutional investors own 35.03% of the company’s stock.

Zevra Therapeutics Stock Performance

Shares of Zevra Therapeutics stock opened at $9.23 on Friday. The company has a debt-to-equity ratio of 0.40, a current ratio of 5.68 and a quick ratio of 5.63. The firm has a 50 day simple moving average of $9.05 and a 200 day simple moving average of $9.11. Zevra Therapeutics has a fifty-two week low of $6.19 and a fifty-two week high of $13.16. The firm has a market cap of $541.89 million, a P/E ratio of 6.94 and a beta of 0.91.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome.